Review
doi: 10.1016/s0952-7915(99)00017-5.
A new era for radiolabeled antibodies in cancer?
Affiliations
- PMID: 10508716
- DOI: 10.1016/s0952-7915(99)00017-5
Item in Clipboard
Review
A new era for radiolabeled antibodies in cancer?
Curr Opin Immunol.
1999 Oct.
Abstract
Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times higher than to the normal tissue with the next highest dose. RIT appears promising for future cancer therapy. Clinical responses in patients with advanced cancer have frequently been achieved with RIT as a single agent. Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy.
Similar articles
-
Status of radioimmunotherapy in the new millennium.Cancer Biother Radiopharm. 2001 Jun;16(3):237-56. doi: 10.1089/10849780152389429. Cancer Biother Radiopharm. 2001. PMID: 11471488 Review.
-
Radioimmunotherapy: recent results and future directions.J Clin Oncol. 1996 Apr;14(4):1383-400. doi: 10.1200/JCO.1996.14.4.1383. J Clin Oncol. 1996. PMID: 8648397 Review.
-
Antibody-based targeted radiation to pediatric tumors.J Nucl Med. 2005 Jan;46 Suppl 1:157S-63S. J Nucl Med. 2005. PMID: 15653664 Review.
-
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.J Nucl Med. 2005 Jan;46 Suppl 1:115S-27S. J Nucl Med. 2005. PMID: 15653660 Review.
-
Radioimmunotherapy with monoclonal antibodies. A new horizon in nuclear medicine therapy?Nuklearmedizin. 1994 Aug;33(4):167-73. Nuklearmedizin. 1994. PMID: 7971292 Review.
Cited by
-
Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody.Cancer Immunol Immunother. 2004 Jun;53(6):533-42. doi: 10.1007/s00262-003-0460-1. Epub 2004 Jan 13. Cancer Immunol Immunother. 2004. PMID: 14722669 Free PMC article.
-
Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).Exp Ther Med. 2010 Mar;1(2):233-240. doi: 10.3892/etm_00000037. Exp Ther Med. 2010. PMID: 21494315 Free PMC article.
-
Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma.ACS Nano. 2018 Feb 27;12(2):1544-1563. doi: 10.1021/acsnano.7b08122. Epub 2018 Jan 26. ACS Nano. 2018. PMID: 29361211 Free PMC article.
-
Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? For.Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1248-54. doi: 10.1007/s00259-002-0928-9. Eur J Nucl Med Mol Imaging. 2002. PMID: 12418465 No abstract available.
-
Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.Indian J Med Res. 2016 Jan;143(1):57-65. doi: 10.4103/0971-5916.178593. Indian J Med Res. 2016. PMID: 26997015 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
